

PARTI	Transited Decule for the Quarter and Nine months Ended 31/12/2017	Its for the Ough	ter and Nine mo	nths Ended 31/1	2/2017	
Statement of Standalone	Unaudited Nesu	ווא זמו מווג לחיייו	7.7	Voor to doto	Voar to date	Previous
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	figures for current period ended	figures for current period ended	year ended
	(31/12/2017)	(30/09/2017)	(31/12/2016)	(31/12/2017)	(31/12/2016)	(31/03/2017)
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from Operation				00 101	217 07	517.23
Other Operating Revenue	328.45	5.75	132.94	435.02	2000	070
Ulici Operanis income	1.67	2.94	96.0	6.61	3.39	2.00
III Total Revenue (I + II)	330.12	8.69	133.90	441.63	321.26	18.81
IV Expenses			1000	100 55	70.15	86.07
(a) Cost of materials consumed	97.18	(13.62)	6.07	0000	000	0.00
(h) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	12.03
C Changes in inventories of finished goods,	(16.95)	(16.95)	(0.45)	0.00	3.17	CO.71
work-in-progress and stock-in-trade				10.10	04 60	11821
(d) Employee benefits expense	34.11	. 31.42	35.09	91.37	00.00	000
(e) Finance Cost	0.59	0.00	0.00	0.78	33.60	46.59
(A) Depreciation and amortisation expense	17.50	7.50	9.25	37.30	23.00	152.00
(y) Other expenses	59.96	(0.61)	48.22	47.95	/8.38	132.03
(0)	00 001	NT L	11895	286.16	269.90	414.99
Total expenses	194.39	1.1.	14.05	155 47	51.36	104.59
V Profit / (Loss)before exceptional and extraordinary items and tax (III - IV)	137,73	0.95	14.93	1.001		
	000	0.00	0.00	00.00	0.00	0.00
VII Profit / (Loss) before extraordinary items and tax (V - VI)	137.73	0.95	14.95	155.47	51.36	104.59
VIII Extraordinary items	00:00	0.00	0.00	0.00	0.00	0.00
,		300	14 05	155.47	51.36	104.59
IX Profit before tax (VII- VIII)	15/,/3	0.9.0	CHI			i c
T. Browieion for tayation	41.32	0.29	4.50	46.64	16.00	38.71
XI Net Profit / (Loss) or the period (VII-VIII)		99:0	10.45	108.83	35.36	65.88
		000	0.00	0.00	0.00	0.00
XII Other Comprehensive Income/(Loss) (net of tax) (Refer Not No. 5)	0.00	00.00				
		270	10.45	108.83	35.36	65.88

CIN: L24231GJ1993PLC019079



## PHARMACEUTICALS L

								_
						10000	15657	_
×	XV Paid up Equity Share Capital (Face value	156.57	156.57	156.57	156.57	156.57	120.27	
	of Re 10/- each)							7
	OI MAN TOLONOMY							_
								_
5	CVI Comings nor aquity share:						0,0	т"
1	Latinings per equity sum of	0,0	000	0.07	0.70	0.23	0.47	
	(1) Pacin	0.07	0.00	0.0			07.0	
	(I) Dasic	500	000	0.07	0.70	0.23	0.47	
L	(2) Diluted	70.0	0.00					1
_	Thursday, and the state of the							

Notes:

1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 13th February, 2018

2. The Company has only single Reportable Business Segment.

3. During the quarter ended 31st December, 2017, Nil complaints was received and attended.

4. Previous quarter's figures have been re-grouped / re-arranged wherever necessary

these financial have been prepared in accordance with the recognition and measurements principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with 5. The Company has adopted Indian Accounting Standarads ("IND AS") from April 1, 2017 and accordingly the relavent rules issued thereunder and other accounting principles generally accepted in India. Financial Results for the previous period have been prepared in accordance with recognition and measurements

ent of Profit and Loss reported for previous year under IGAAP to Ind AS Quarter Ended December 31, 2016 ninciple of Ind AS 34

		~	Effect on	
Particulars	Item Impacting As Per IGAA Transition to As Per Ind AS Ind AS	As Per IGAAl	Transition to Ind AS	As Per Ind AS
				100001
Designing from Onerations		132.94	0	132.34
Veveline Hour Sportments		000	<	900
Other Comprehensive Income		0.96	0	0.70
Office Comprehensive ancounce		01.		7.50
T. Evmonda		4.50	0	4.30
I ax Expenses		1.		10.45
CA A Barr Town		10.45		CT:01
Profit After lax				

December 31, 2016 Reconciliation of Statement of Profit and

			Ellect on	
Doction	Item Impacting   As Per IGAA Transition to   As Per Ind AS	As Per IGAA	Transition to	As Per Ind AS
r at ticutats			Ind AS	
		1	d	71707
Daylania from Operations		317.87	0	21/.0/
Nevellue from Operation		000		2 20
Other Comprehensive Income		3.39	0	2.37
Ourer Countries of the care		0001	c	16.00
Tow Evenoneer		16.00	0	10.00
I ax Expelleds		7636		75 36
Profit After Tax		55.30	0	00:00
I TOTAL TIME				

Place: Ahmedabad Date: 13/02/2018

For Shukra Pharmaceuticals Limited By Order of the Board of Directors

Chandresh Patel

DIN: 07032481

Director

CIN: L24231GJ1993PLC019079